Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

NCT07046806

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Institute for Asthma and Allergy
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (10)

- Provision of written informed consent.
- Male or female, aged e18 at the time of provision of informed consent.
- Diagnosis of bradykinin-mediated angioedema based upon all of the following:
- Clinical history consistent with angioedema (subcutaneous or mucosal, nonpruritic swelling without accompanying urticaria), not responsive to treatments of anti-histamine, corticosteroid, and/or omalizumab.
- Tried and failed at least 2 weeks of cetirizine 20 mg twice a day (or its equivalent alternative antihistamines, such as fexofenadine, loratadine, desloratadine or levocetirizine, etc.).

... and 5 more (see full listing online)

Exclusion (14)

- Any diagnosis of angioedema other than BK-AE-nC1INH.
- Participation in a clinical study with any other investigational drug within the previous 30 days or within 5 half-lives of the investigational drug at Screening (whichever was longer).
- Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as oral contraceptives or hormonal replacement therapy) within 4 weeks of Screening.
- Receiving prophylactic treatment for BK-AE-nC1INH. Participants who have previously received prophylactic therapy but have stopped can participate in this study provided a sufficiently long washout period (e5 half-life) is observed before the participant is screened. Exclusion includes use of:
- • Short-term prophylaxis for BK-AE-nC1INH within 7 days prior to Screening.

... and 9 more (see full listing online)

Locations (1 total)

Institute For Asthma & Allergy, Wheaton, Maryland, United States